secwatch.observer — SEC 8-K summary
======================================

Issuer:     Opus Genetics, Inc. (IRD)
CIK:        0001228627
Form:       8-K
Filed at:   2023-11-27T23:59:59+00:00
Accession:  0001140361-23-054632
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocuphire Pharma appoints Joseph Schachle COO; $400K salary, 300K option grant
-----------------------------------------------------------------------------

- Joseph Schachle appointed COO effective Nov 27, 2023; previously COO of Opus Genetics.
- Base salary $400K, target annual bonus 45% of base, 300K stock option grant.
- Stock option vests 25% on 1-year anniversary, remaining monthly over 36 months.
- Appointment part of strategic initiative to advance lead retina asset APX3330 into registrational studies.
- Severance: 9 months salary continuation plus COBRA reimbursement if terminated without cause or for good reason.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1228627/000114036123054632/0001140361-23-054632-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1228627/000114036123054632/ef20015189_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-054632

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer